Analyzing the Spatial Distribution of Immune Cells in Lung Adenocarcinoma

Overview

Journal J Pers Med

Date 2024 Sep 28

PMID 39338178

Authors

Florina Almarii

Maria Sajin

George Simion

Simona O Dima

Vlad Herlea

Affiliations

Soon will be listed here.

Abstract

(1) Background: This study investigates the tumor immune microenvironment, focusing on immune cell distribution in lung adenocarcinoma. (2) Methods: We evaluated fifty cases of lung adenocarcinoma, and suitable areas for further studies were annotated on the histological slides. Two tumor cores per case were obtained, one from the tumor's center and another from its periphery, and introduced into three paraffin receptor blocks for optimized processing efficiency. The 4-micrometer-thick tissue microarray sections were stained for H&E and for CD68, CD163, CD8, CD4, and PD-L1; (3) Results: Our investigation revealed significant correlations between PD-L1 expression in tumor cells and the presence of CD163+ macrophages, between CD4+ cells and CD8+, CD68+, and CD163+ cells, and also between CD8+ T cells and CD163+ cells. Additionally, while we observed some differences in cellular components and densities between the tumor center and periphery, these differences were not statistically significant. However, distinct correlations between PD-L1 and immune cells in these regions were identified, suggesting spatial heterogeneity in the immune landscape. (4) Conclusions: These results emphasize the intricate interactions between immune cells and tumor cells in lung adenocarcinoma. Understanding patient spatial immune profile could improve patient selection for immunotherapy, ensuring that those most likely to benefit are identified.

References

Thommen D, Schumacher T . T Cell Dysfunction in Cancer. Cancer Cell. 2018; 33(4):547-562. PMC: 7116508. DOI: 10.1016/j.ccell.2018.03.012. View

Sun Y, Yang Q, Shen J, Wei T, Shen W, Zhang N . The Effect of Smoking on the Immune Microenvironment and Immunogenicity and Its Relationship With the Prognosis of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer. Front Cell Dev Biol. 2021; 9:745859. PMC: 8512705. DOI: 10.3389/fcell.2021.745859. View

Fu T, Dai L, Wu S, Xiao Y, Ma D, Jiang Y . Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response. J Hematol Oncol. 2021; 14(1):98. PMC: 8234625. DOI: 10.1186/s13045-021-01103-4. View

Yang L, Zhang W, Sun J, Yang G, Cai S, Sun F . Functional status and spatial interaction of T cell subsets driven by specific tumor microenvironment correlate with recurrence of non-small cell lung cancer. Front Immunol. 2023; 13:1022638. PMC: 9846487. DOI: 10.3389/fimmu.2022.1022638. View

Huang M, Lou Y, Pellissier J, Burke T, Liu F, Xu R . Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States. Pharmacoeconomics. 2017; 35(8):831-844. PMC: 5548835. DOI: 10.1007/s40273-017-0527-z. View

Su S, Chen F, Xu M, Liu B, Wang L . Recent advances in neoantigen vaccines for treating non-small cell lung cancer. Thorac Cancer. 2023; 14(34):3361-3368. PMC: 10693939. DOI: 10.1111/1759-7714.15126. View

Schietinger A, Philip M, Liu R, Schreiber K, Schreiber H . Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase. J Exp Med. 2010; 207(11):2469-77. PMC: 2964573. DOI: 10.1084/jem.20092450. View

Dehne N, Mora J, Namgaladze D, Weigert A, Brune B . Cancer cell and macrophage cross-talk in the tumor microenvironment. Curr Opin Pharmacol. 2017; 35:12-19. DOI: 10.1016/j.coph.2017.04.007. View

Kersten K, Hu K, Combes A, Samad B, Harwin T, Ray A . Spatiotemporal co-dependency between macrophages and exhausted CD8 T cells in cancer. Cancer Cell. 2022; 40(6):624-638.e9. PMC: 9197962. DOI: 10.1016/j.ccell.2022.05.004. View

10.

Gibbons D, Byers L, Kurie J . Smoking, p53 mutation, and lung cancer. Mol Cancer Res. 2014; 12(1):3-13. PMC: 3925633. DOI: 10.1158/1541-7786.MCR-13-0539. View

11.

Mamdani H, Matosevic S, Khalid A, Durm G, Jalal S . Immunotherapy in Lung Cancer: Current Landscape and Future Directions. Front Immunol. 2022; 13:823618. PMC: 8864096. DOI: 10.3389/fimmu.2022.823618. View

12.

Dong Z, Zhong W, Zhang X, Su J, Xie Z, Liu S . Potential Predictive Value of and Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res. 2017; 23(12):3012-3024. DOI: 10.1158/1078-0432.CCR-16-2554. View

13.

Liu F, Liu W, Zhou S, Yang C, Tian M, Jia G . Identification of FABP5 as an immunometabolic marker in human hepatocellular carcinoma. J Immunother Cancer. 2020; 8(2). PMC: 7332195. DOI: 10.1136/jitc-2019-000501. View

14.

Guo F, Feng Y, Zhao G, Zhang R, Cheng Z, Kong W . Tumor-Associated CD163 M2 Macrophage Infiltration is Highly Associated with PD-L1 Expression in Cervical Cancer. Cancer Manag Res. 2020; 12:5831-5843. PMC: 7369418. DOI: 10.2147/CMAR.S257692. View

15.

Parra E, Villalobos P, Zhang J, Behrens C, Mino B, Swisher S . Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors. J Thorac Oncol. 2018; 13(6):779-791. DOI: 10.1016/j.jtho.2018.03.002. View

16.

Wu Y, Yuan M, Wang C, Chen Y, Zhang Y, Zhang J . T lymphocyte cell: A pivotal player in lung cancer. Front Immunol. 2023; 14:1102778. PMC: 9911803. DOI: 10.3389/fimmu.2023.1102778. View

17.

Lakatos E, Williams M, Schenck R, Cross W, Househam J, Zapata L . Evolutionary dynamics of neoantigens in growing tumors. Nat Genet. 2020; 52(10):1057-1066. PMC: 7610467. DOI: 10.1038/s41588-020-0687-1. View

18.

Shima T, Shimoda M, Shigenobu T, Ohtsuka T, Nishimura T, Emoto K . Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma. Cancer Sci. 2019; 111(2):727-738. PMC: 7004546. DOI: 10.1111/cas.14272. View

19.

Liu W, You W, Lan Z, Ren Y, Gao S, Li S . An immune cell map of human lung adenocarcinoma development reveals an anti-tumoral role of the Tfh-dependent tertiary lymphoid structure. Cell Rep Med. 2024; 5(3):101448. PMC: 10983046. DOI: 10.1016/j.xcrm.2024.101448. View

20.

Lahiri A, Maji A, Potdar P, Singh N, Parikh P, Bisht B . Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023; 22(1):40. PMC: 9942077. DOI: 10.1186/s12943-023-01740-y. View